Cigna Corp (CI) Gets a Buy Rating from Credit Suisse

By Carrie Williams

In a report released today, A.J. Rice from Credit Suisse maintained a Buy rating on Cigna Corp (CIResearch Report), with a price target of $250. The company’s shares opened today at $186.50.

According to, Rice is a 4-star analyst with an average return of 8.0% and a 57.4% success rate. Rice covers the Services sector, focusing on stocks such as Quest Diagnostics Inc, Genesis Healthcare, and Acadia Healthcare.

Cigna Corp has an analyst consensus of Strong Buy, with a price target consensus of $240.21, implying a 28.8% upside from current levels. In a report issued on December 24, Edward Jones also initiated coverage with a Buy rating on the stock.


See today’s analyst top recommended stocks >>

The company has a one-year high of $226.61 and a one-year low of $163.97. Currently, Cigna Corp has an average volume of 2.75M.

Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Jason Sadler, the Pres., International Markets of CI sold 21,189 shares for a total of $4,512,833.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cigna Corp. is a global health service company, which is dedicated to improving the health, well-being and peace of mind. The company delivers choice, predictability, affordability and quality care through integrated capabilities and connected, personalized solutions that advance whole person health.